A Phase I study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) in combination with tremelimumab in patients with advanced solid tumors. (4th November 2015) - Papadopoulos, Kyriakos P; Tsai, Frank; Hamid, Omid; Xiao, Feng; Steele, Keith E; Rebelatto, Marlon C; Robbins, Paul B; Karakunnel, Joyson J; Lai, Dominic W; Mahipal, Amit